Physician profile
Daniel Krauser
NPI 1740338912
$3,424.94
in general payments reported to CMS, 2019-2025
19 companies · $76.36 in 2025
The $76.36 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,702 · 2020: $467 · 2023: $43.82 · 2024: $135 · 2025: $76.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $338.92 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $334.14 | 2019-2020 | |
| Amgen INC. | $293.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $235.33 | 2019-2020 | |
| Amarin Pharma, INC. | $214.93 | 2019-2020 | |
| Boston Scientific Corporation | $213.82 | 2019-2020 | |
| Novo Nordisk INC | $204.53 | 2019-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $201.76 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $200.55 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $191.59 | 2019-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.49 | 2019-2020 | |
| Pfizer INC. | $162.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $158.00 | 2019-2020 | |
| Lilly USA, LLC | $153.20 | 2019-2024 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $127.84 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $116.90 | 2019-2020 | |
| Baxter Healthcare | $56.47 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Irhythm Technologies, INC. | $31.10 | 2024 | Zio Xt Patch, Zio Monitor |
| Astellas Pharma US INC | $24.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Krauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.